ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2070

Cytokine Profiles In Polymyositis and Dermatomyositis Complicated With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease Or Anti-Aminoacyl tRNA Synthetase Antibody-Associated Interstitial Lung Disease

Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Hidenaga Kawasumi, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantibodies, cytokines and myositis, Lung Disease, Pathophysiology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Polymyositis (PM) / dermatomyositis (DM) are often complicated with interstitial lung disease (ILD). In PM/DM, complication with ILD is associated with anti-aminoacyl-tRNA synthetase (ARS), including Jo-1 Ab or anti-melanoma differentiation-associated gene 5 (MDA-5) Ab. Clinically amyopathic DM (CADM) patients with anti-MDA-5 Ab have frequent complications with rapidly progressive (RP) ILD, especially in East Asia, where it is classified as acute interstitial pneumonia and reflects diffuse alveolar damage upon pathological examination. In contrast, chronic ILD is frequently observed in anti-ARS Ab-associated PM/DM, which responds well to treatment with corticosteroids. The response to treatment and the mortality rate are different between anti-MDA-5 Ab-associated ILD (anti-MDA-5-ILD) and anti-ARS Ab-associated ILD (anti-ARS-ILD). The differences in pathophysiology between these two Ab-associated ILD subsets remain unknown. Therefore, we investigate various serum cytokines in patients with PM/DM with ILD, and then clarify the differences in pathophysiology between anti-MDA-5-ILD and anti-ARS-ILD.

Methods: We evaluated the serum cytokine profiles of 38 patients with PM/DM and compared the cytokine profiles of 17 patients without ILD (non-ILD subset) and 21 patients with ILD (ILD subset), as well as the anti-MDA5-ILD and anti-ARS-ILD subsets. The levels of serum cytokines, including IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, TNF-α, IFN-α, IFN-γ, and interferon γ-inducible 10-kd (IP-10), were measured by multiplex assay. In addition, serum was obtained from 15 healthy controls (HCs).

Results: Serum IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, IFN-α, IFN-γ and IP-10 were significantly higher in PM/DM patients than HCs. Moreover, the levels of IL-4, IL-6, IL-8, IL-10, TNF-α and IP-10 were significantly higher in the ILD subset than the non-ILD subset. By multivariate analysis, TNF-α was the most significant cytokine (P = 0.0006, odds ratio 1.4, CI 1.1-2.2) associated with PM/DM with ILD. Regarding to the comparison between 10 patients with anti-MDA-5-ILD and 11 patients with anti-ARS-ILD, IL-8 level was significantly higher in the anti-MDA-5-ILD subset than the anti-ARS-ILD subset. Lower levels of IL-4 and higher levels of IL-10 and IFN-α were found in the anti-MDA-5-ILD subset than those in the anti-ARS-ILD subset. By multivariate analysis, IL-8 was the most cytokine that was most significantly associated with anti-MDA-5-ILD (P = 0.0006, odds ratio 1.5, confidence interval [CI] 1.1-3.0). In addition, the IL-4 level was inversely associated with anti-MDA-5-ILD (P = 0.01, odds ratio 0.8, CI 0.6-0.98). Moreover, the ratio of serum IL-4 to IFN-γ, which may reflect a balance between T helper 1 (TH1) and 2 (TH2) cells, was lower in anti-MDA-5-ILD (median value 0.16) than in anti-ARS-ILD (median value 2.0).

Conclusion: TNF-α is an especially important in contributing to ILD in PM/DM. Serum IL-8 levels and the balance between IL-4 and IFN-γ may contribute to the differences in pathophysiology between chronic ILD (anti-ARS-ILD) and RP-ILD (anti-MDA-5-ILD).


Disclosure:

T. Gono,
None;

Y. Kawaguchi,
None;

H. Kaneko,
None;

Y. Katsumata,
None;

M. Hanaoka,
None;

S. Kataoka,
None;

H. Kawasumi,
None;

K. Takagi,
None;

H. Ichida,
None;

S. Baba,
None;

Y. Okamoto,
None;

Y. Ota,
None;

H. Yamanaka,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cytokine-profiles-in-polymyositis-and-dermatomyositis-complicated-with-anti-melanoma-differentiation-associated-gene-5-antibody-associated-interstitial-lung-disease-or-anti-aminoacyl-trna-synthetase-a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology